Literature DB >> 15105109

In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Paul G Higgins1, Hilmar Wisplinghoff, Danuta Stefanik, Harald Seifert.   

Abstract

Acinetobacter baumannii is an important nosocomial pathogen usually in the context of serious underlying disease. Multidrug resistance in these organisms is frequent. The beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam have intrinsic activity against Acinetobacter strains. To evaluate their potential therapeutic usefulness, we determined the in vitro activity of ampicillin, sulbactam, ampicillin-sulbactam, cefoperazone, cefoperazone-sulbactam, piperacillin, piperacillin-sulbactam, tazobactam, piperacillin-tazobactam, amoxicillin, clavulanic acid, amoxicillin-clavulanic acid, ticarcillin, and ticarcillin-clavulanic acid against multidrug-resistant A. baumannii. All isolates were epidemiologically characterized by RAPD [random(ly) amplified polymorphic DNA] analysis and/or pulsed-field gel electrophoresis and represented different strain types, including sporadic strains, as well as outbreak-related strains. The MICs were determined by agar dilution on Mueller-Hinton agar (using fixed concentrations, as well as fixed ratios for beta-lactamase inhibitors) and the E-test. The majority of E-test results were within two dilutions of those recorded by agar dilution, with the exception of piperacillin-tazobactam. Sulbactam was superior to clavulanic acid and tazobactam and may represent an alternative treatment option for infections due to multiresistant A. baumannii strains. beta-Lactamase inhibitors have intrinsic activity but do not enhance activity of beta-lactams against A. baumannii. Testing with the inhibitor added at a fixed concentration as recommended for piperacillin-tazobactam and ticarcillin-clavulanic acid by the National Committee for Clinical Laboratory Standards may falsely suggest high activity or gives uninterpretable results due to trailing. If combinations are used for testing, fixed ratios may give more useful results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105109      PMCID: PMC400525          DOI: 10.1128/AAC.48.5.1586-1592.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia.

Authors:  M J Rodríguez-Hernández; J Pachón; C Pichardo; L Cuberos; J Ibáñez-Martínez; A García-Curiel; F J Caballero; I Moreno; M E Jiménez-Mejías
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

2.  Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).

Authors:  I Simpson; J Durodie; S Knott; B Shea; J Wilson; K Machka
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

3.  Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.

Authors:  M B Marques; E S Brookings; S A Moser; P B Sonke; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam.

Authors:  M E Jiménez-Mejías; J Pachón; B Becerril; J Palomino-Nicás; A Rodríguez-Cobacho; M Revuelta
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

5.  Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii.

Authors:  X Corbella; J Ariza; C Ardanuy; M Vuelta; F Tubau; M Sora; M Pujol; F Gudiol
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

6.  In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Authors:  M Wolff; M L Joly-Guillou; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.

Authors:  B Heinemann; H Wisplinghoff; M Edmond; H Seifert
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

8.  Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of Acinetobacter spp.

Authors:  H J Grundmann; K J Towner; L Dijkshoorn; P Gerner-Smidt; M Maher; H Seifert; M Vaneechoutte
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

9.  Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain.

Authors:  S López-Hernández; T Alarcón; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

10.  In vitro activities of ampicillin-sulbactam and amoxicillin-clavulanic acid against Acinetobacter baumannii.

Authors:  A Pandey; A Kapil; S Sood; V Goel; B Das; P Seth
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

View more
  30 in total

1.  Severe pneumonia in the elderly: a multivariate analysis of risk factors.

Authors:  Wei Li; Cheng Ding; Shaojun Yin
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  "All-in-one-plate" E-test and disk diffusion susceptibility co-testing for multiresistant Acinetobacter baumannii.

Authors:  J Gilad; M Giladi; F Poch; Y Aharoni; D Schwartz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

Review 3.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 4.  Zinc and antibiotic resistance: metallo-beta-lactamases and their synthetic analogues.

Authors:  A Tamilselvi; Govindasamy Mugesh
Journal:  J Biol Inorg Chem       Date:  2008-07-22       Impact factor: 3.358

5.  Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.

Authors:  William F Penwell; Adam B Shapiro; Robert A Giacobbe; Rong-Fang Gu; Ning Gao; Jason Thresher; Robert E McLaughlin; Michael D Huband; Boudewijn L M DeJonge; David E Ehmann; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

6.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

7.  Multidrug resistant acinetobacter.

Authors:  Vikas Manchanda; Sinha Sanchaita; Np Singh
Journal:  J Glob Infect Dis       Date:  2010-09

8.  High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004.

Authors:  Kyungwon Lee; Chang Hyun Lim; Ji Hyun Cho; Wee Gyo Lee; Young Uh; Hwi Jun Kim; Dongeun Yong; Yunsop Chong
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

Review 9.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

10.  Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.

Authors:  Sutep Jaruratanasirikul; Wibul Wongpoowarak; Thitima Wattanavijitkul; Waroonrat Sukarnjanaset; Maseetoh Samaeng; Monchana Nawakitrangsan; Natnicha Ingviya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.